At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 402 enrolled
Drug / intervention
DHA (Docosahexaenoic Acid) +1 moredrug
Likely dose
DHA (Docosahexaenoic Acid) 950 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease
Alzheimer's Disease Cooperative Study (ADCS)·interventional·Posted Feb 26, 2007·Updated Sep 25, 2014
In Brief
A Phase 3 clinical trial evaluating DHA (Docosahexaenoic Acid) and Placebo for Alzheimer's Disease. Completed, enrolled 402 participants across 51 sites.
Detailed Summary
The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedFeb 2007
Primary CompletionMay 2009
TodayJul 2026
First PostedFeb 26, 2007
Enrollment StartFeb 1, 2007
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.3 years ago
Interventions
DHA (Docosahexaenoic Acid)drug
950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months
Placebodrug
2 placebo capsules twice a day for 18 months